Loading clinical trials...
Loading clinical trials...
Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)
Conditions
Interventions
MET097
Placebo
Locations
196
United States
Headlands Research
Scottsdale, Arizona, United States
Alliance Research Institute
Canoga Park, California, United States
Clinical Innovations, Inc dba CITrials
Riverside, California, United States
Peninsula Headlands LLC
Rolling Hills, California, United States
Collaborative Neuroscience Research, LLC
Torrance, California, United States
CenExcel Rocky Mountain Clinical Research, LLC
Englewood, Colorado, United States
Start Date
December 29, 2025
Primary Completion Date
September 1, 2027
Completion Date
May 1, 2028
Last Updated
April 21, 2026
NCT07049861
NCT06623669
NCT06976307
NCT06636773
NCT06878989
NCT06935838
Lead Sponsor
Metsera, a wholly owned subsidiary of Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions